Search

Your search keyword '"Moric Peric, Martina"' showing total 20 results
Start Over Author "Moric Peric, Martina"
20 results on '"Moric Peric, Martina"'

3. Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis

Author

Lucijanic, Marko, primary, Krecak, Ivan, additional, Soric, Ena, additional, Sabljic, Anica, additional, Galusic, Davor, additional, Holik, Hrvoje, additional, Perisa, Vlatka, additional, Moric Peric, Martina, additional, Zekanovic, Ivan, additional, Budimir, Josipa, additional, and Kusec, Rajko, additional

Published
2024
Full Text
View/download PDF

6. Systemic Inflammatory Index in Polycythemia Vera and Its Prognostic Implications.

Author

Krecak, Ivan, Lekovic, Danijela, Arsenovic, Isidora, Bogdanovic, Andrija, Holik, Hrvoje, Zekanovic, Ivan, Moric Peric, Martina, and Lucijanic, Marko

Subjects
PLATELET lymphocyte ratio, NEUTROPHIL lymphocyte ratio, POLYCYTHEMIA vera, PLATELET count, MYELOPROLIFERATIVE neoplasms
Abstract

Background: This study aimed to evaluate the clinical and prognostic associations of the systemic inflammatory index (SII) in polycythemia vera (PV) patients. SII integrates information on absolute neutrophil (ANC), lymphocyte (ALC), and platelet counts into one index (calculated as ANCxALC/platelet count) and was previously shown to predict thrombotic and mortality risks in the general population. Methods: A total of 279 PV patients treated in several hematologic centers in Croatia and Serbia was retrospectively evaluated. Results: The median SII for the overall cohort was 1960. Higher SII stratified at the specific cut-off points was significantly associated with shorter time to thrombosis (TTT; p = 0.004) driven by arterial thrombotic events, and shorter overall survival (OS; p < 0.001). Higher SII was able to refine the European Leukemia Net-defined high-risk patient subgroup for both thrombotic and survival risks, especially in individuals over 60 years of age. SII and all other evaluated CBC components and indices (leukocytes, ANC, ALC, platelets, neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR)) demonstrated low-to-modest prognostic properties, whereas SII outperformed other parameters with respect to TTT and OS prognostications. Discussion: The presented results complement prior studies evaluating the prognostic performance of different CBC components for thrombotic and survival risk predictions and offer more options to personalize PV treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Purine Analogues Increase the Risk of Lethal and/or Prolonged COVID19 While Obinutuzumab Increases the Risk of Prolonged but Not Lethal Infection in Patients Treated for Lymphoid Malignancies -a Study of Krohem, the Croatian Group for Hematologic Diseases

Author

Aurer, Igor, primary, Jaksic, Ozren, additional, Bašić-Kinda, Sandra, additional, Mrdenovic, Stefan, additional, Ostojic Kolonic, Slobodanka, additional, Lozic, Dominik, additional, Holik, Hrvoje, additional, Novakovic Coha, Sabina, additional, Bernes, Petra, additional, Krecak, Ivan, additional, Moric Peric, Martina, additional, Narancic, Marino, additional, Mitrovic, Zdravko, additional, and Valkovic, Toni, additional

Published
2021
Full Text
View/download PDF

14. Clinical Features and Treatment Outcomes of Grey Zone Lymphoma (GZL), Unclassifiable B-Cell Lymphoma with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma - a Real-Life Multicenter Study By the Croatian Cooperative Group for Hematologic Diseases (KroHem)

Author

Hude, Ida, Brčić, Klara, Morić Perić, Martina, Milunović, Vibor, Vujčić, Milan, Krecak, Ivan, Mitrović, Zdravko, Coha, Božena, Gašparov, Slavko, Dotlić, Snježana, Ilić, Ivana, Bašić-Kinda, Sandra, Aurer, Igor, and Rinčić, Goran

Published
2023
Full Text
View/download PDF

15. Incidence of Secondary Primary Malignancies after Long-Term Follow up of Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation - Report from Croatian Cooperative Group for Hematologic Malignancies (KroHem)

Author

Batinic, Josip, Dreta, Barbara, Radić-Krišto, Delfa, Galusic, Davor, Sinčić Petričević, Jasminka, Holik, Hrvoje, Krecak, Ivan, Morić Perić, Martina, Zekanović, Ivan, Piršić, Mario, Jakšić, Ozren, Rinčić, Goran, Valković, Toni, Sertić, Dubravka, Serventi Seiwerth, Ranka, Rončević, Pavle, Bojanić, Ines, Berneš, Petra, Romić, Ilenia, Mazić, Sanja, and Bašić-Kinda, Sandra

Published
2023
Full Text
View/download PDF

20. eBEACOPP for front-line treatment of patients with classical Hodgkin lymphoma (cHL) in the real world setting

Author

Basic-Kinda, Sandra, Dujmovic, Dino, Radman, Ivo, Moric Peric, Martina, Hude, Ida, Durakovic, Nadira, Vodanovic, Marijo, Dobrenic, Margareta, Kralik, Marko, Galunic-Bilic, Lea, Dotlic, Snjezana, and Aurer, Igor

Subjects
eBEACOOP, Hodgkin lymphoma, outpatient
Abstract

We started using eBEACOPP for front-line treatment of cHL patients 15 years ago ; first within clinical trials, then in high-risk patients with advanced disease and finally in all younger than 60 except those with limited stage and favorable prognosis. Here we describe our experience. We treated 112 patients, 19–69 years old (median 29). Median fol low-up is 40 months. 5-year PFS is 94% and OS 97%. All patients were treated in an outpatient setting, with regular check ups or telephone contacts at least twice weekly. Toxicity during therapy was significant, 50% patients were hospitalized, mostly for infectious complications. Granulocytopenia gr. 4 occurred in 94%, anemia gr. 3–4 in 67% and trombocytopenia gr. 3–4 in 61% of patients. Non-he matological, non-infectious toxicity was rare ; 12% had neuropathy, most recovered. 2 patients developed allergy to etoposide. 3 patients died of toxicity ; 2 of infection, both failed to report early symptoms. The third died suddenly at home, probably due to pulmonary embo lism. All remaining patients responded to therapy ; 3 relapsed. 2 of the relapses occurred in areas that could have been irradiated. The 3rd was PET negative after 2 cycles of eBEACOPP, so treatment was stopped after the 4th. Slightly more than 50% of women resumed spontaneous menstrual cy cles. Other late toxicities were rare. Avascular hip necrosis decreased significantly after we stopped using methlyprednisolone and reduced the number of days on steroids to 8 per cycle. A single patient developed secondary cancer, acute myeloid leukemia. 2 patients have symptomatic heart disease, both were older than 60 at time of treatment and had mediastinal irradiation. In conclusion, eBEACOPP is a very effective and feasible outpatient reg imen for front-line treatment of patients with cHL younger than 60 pro vided it is delivered by a dedicated and experienced team. Acute toxicity is almost universal ; in order to avoid unnecessary deaths patients must be disciplined and have fast access to adequate medical care. Treatment reductions should only be performed after careful considerations. In pa tients interested in preserving fertility sperm cryopreservation should be offered to men and GnRH analogues to women. Other late toxicities are rare, and most cHL survivors treated with eBEACOPP are able to return to a normal and productive life.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results